This guide analyzes how artificial intelligence – including machine learning – can be used by pharmaceutical and medical device companies to improve the clinical data review and cleansing process.
Demographics in clinical trials have always been scrutinized by the medical community and the public. Are various races, ethnicities, sexes, and ages fairly represented in trials? Does one segment respond better or worse than another to a particular treatment? These questions and more are being answered in Drug Trials Snapshots, a section of the FDA’s website that was created to be easily digestible.
In an effort to be more transparent and to help people understand the benefits and side effects among different groups, the FDA is committed to publishing a snapshot for each new drug within 30 days of its approval date. Each snapshot consists of questions and answers about the drug, the demographics of the subjects who took part in the trials, as well as graphs that help depict the statistics. Drug labels can also be accessed from the snapshot.
To date, there are over 40 Drug Trial Snapshots.